CAR-T細胞療法市場規模、佔有率和成長分析（按產品類型、標靶、適應症、治療方法、人口統計、給藥方式和地區分類）—2026-2033年產業預測

全球 CAR T 細胞療法市場規模預計在 2024 年達到 50 億美元，從 2025 年的 69.1 億美元成長到 2033 年的 920 億美元，在預測期（2026-2033 年）內複合年成長率為 38.2%。

CAR-T細胞療法市場正經歷顯著成長，這主要得益於其在骨髓惡性腫瘤治療方面的巨大潛力、全球癌症發病率的上升以及對個性化治療日益成長的需求。基因編輯技術的創新和大型製藥公司的巨額投資，在有利的法規環境下，進一步推動了先進CAR-T細胞療法的研發。已通過核准治療方法的卓越療效增強了相關人員的信任，並擴大了患者的治療範圍，尤其是在醫療體系發達的國家。然而，高昂的治療費用、複雜的生產過程以及相關的不利事件等挑戰限制了CAR-T細胞療法的可及性和市場滲透率。此外，新興經濟體熟練專業人員的短缺和基礎設施的不足，也阻礙了CAR-T細胞療法治療潛力的充分發揮。

全球CAR-T細胞療法市場促進因素

全球CAR-T細胞療法市場預計將迎來顯著成長，這主要歸功於人們對個人化醫療日益成長的興趣。隨著越來越多的患者尋求個人化治療方案，對CAR-T細胞療法的需求預計將大幅增加。這種創新療法的療效可以透過個人化治療方案得到提升，該方案能夠更精準地匹配每位患者的個別特徵。這種客製化不僅能夠改善患者的治療效果，也引起了醫療專業人員和機構的廣泛關注。隨著個人化醫療在治療研發中持續發揮核心作用，CAR-T細胞療法市場有望從這種對個人化治療策略的關注中獲益匪淺。

限制全球CAR-T細胞療法市場的因素

全球CAR-T細胞療法市場面臨與該療法創新相關的重大挑戰。儘管進行了廣泛的測試，但人們對潛在副作用和長期安全性的擔憂仍然突出。這些不確定性可能會限制CAR-T細胞療法在醫療服務提供者和患者中的廣泛接受和應用。在市場相關人員權衡這些風險和利益之際，對全面接受這項突破性治療方法的猶豫可能會阻礙其發展和融入標準治療通訊協定，並有可能在不久的將來影響整個市場的發展。

全球CAR-T細胞療法市場趨勢

全球CAR-T細胞療法市場的一大趨勢是異體CAR-T細胞療法的開發，這種療法無需針對特定患者進行客製化，並簡化了生產流程。這項創新有望提高CAR-T細胞療法的可近性和可負擔性，從而擴大其市場吸引力。隨著各公司致力於開發此類治療方法，它們的目標不僅是改善患者療效，還要在新興市場中佔據有利地位。這種策略轉變可望創造成長機遇，幫助企業拓展業務範圍，同時滿足不同患者群的需求，進而推動整個產業的成長。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球 CAR-T 細胞療法市場規模：按產品和複合年成長率分類（2026-2033 年）

• 耶斯卡塔
• 凱姆裡亞
• 碳水化合物
• 阿別隈
• Tekartas
• 布里安吉
• 其他產品

全球 CAR-T 細胞療法市場規模：按目標和複合年成長率分類（2026-2033 年）

• CD19
• BCMA
• HER2
• 其他目標

全球 CAR-T 細胞療法市場規模（按適應症和複合年成長率分類）（2026-2033 年）

• 多發性骨髓瘤
• B細胞淋巴瘤
• 急性淋巴性白血病
• 其他跡象

全球 CAR-T 細胞療法市場規模：按治療方法和複合年成長率分類（2026-2033 年）

• 單藥治療
• 聯合治療

全球 CAR-T 細胞療法市場規模：按人口統計和複合年成長率分類（2026-2033 年）

• 成人
• 兒童

全球 CAR-T 細胞療法市場規模（按給藥途徑和複合年成長率分類）（2026-2033 年）

• 住院病人
• 門診

全球 CAR-T 細胞療法市場規模（按最終用戶和複合年成長率分類）（2026-2033 年）

• 醫院
• 專業治療中心
• 學術和研究機構

全球CAR-T細胞療法市場規模及複合年成長率（2026-2033年）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Legend Biotech（USA）
• Allogene Therapeutics（USA）
• Cellectis（France）
• Precision BioSciences（USA）
• Arcellx（USA）
• Autolus Therapeutics（UK）
• Immatics NV（Germany）
• Caribou Biosciences（USA）
• Tessa Therapeutics（Singapore）
• Sorrento Therapeutics（USA）
• Precigen, Inc.（USA）
• SinoCellTech（China）
• Celyad Oncology（Belgium）
• Instil Bio（USA）
• Poseida Therapeutics（USA）
• Nkarta, Inc.（USA）
• Tmunity Therapeutics（USA）
• Innovative Cellular Therapeutics（China）
• Miltenyi Biotec（Germany）
• Prescient Therapeutics（Australia）

結論與建議

Global CAR T-Cell Therapy Market size was valued at USD 5 Billion in 2024 and is poised to grow from USD 6.91 Billion in 2025 to USD 92 Billion by 2033, growing at a CAGR of 38.2% during the forecast period (2026-2033).

The CAR T-Cell Therapy market is experiencing significant growth, driven by its transformative potential in treating hematological malignancies and the increasing global cancer prevalence alongside a demand for personalized therapies. Innovations in gene-editing technologies and substantial investments from major pharmaceutical companies have further propelled the development of advanced CAR T-cell therapies, supported by favorable regulatory environments. Notable efficacy in approved therapies has reinforced confidence among stakeholders and expanded patient access, particularly in countries with advancing healthcare systems. Nevertheless, challenges such as exorbitant treatment costs, complex manufacturing processes, and associated adverse events limit accessibility and market penetration. Additionally, a shortage of skilled professionals and inadequate infrastructure in emerging economies poses barriers to leveraging the full therapeutic potential of CAR T-cell therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global CAR T-Cell Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global CAR T-Cell Therapy Market Segments Analysis

Global CAR T-Cell Therapy Market is segmented by Product, Target, Indication, Therapy Type, Demographic, Administration Type, End User and region. Based on Product, the market is segmented into Yescarta, Kymriah, Carvykti, Abecma, Tecartus, Breyanzi and Other Products. Based on Target, the market is segmented into CD19, BCMA, HER2 and Other Targets. Based on Indication, the market is segmented into Multiple Myeloma, B-Cell Lymphoma, Acute Lymphoblastic Leukemia and Other Indications. Based on Therapy Type, the market is segmented into Monotherapy and Combination therapy. Based on Demographic, the market is segmented into Adults and Pediatrics. Based on Administration Type, the market is segmented into Inpatient and Outpatient. Based on End User, the market is segmented into Hospitals, Specialty Centers and Academic & Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global CAR T-Cell Therapy Market

The Global CAR T-Cell Therapy market is poised for significant growth, largely fueled by the rising interest in personalized medicine. As more patients seek tailored treatment options, the demand for CAR T-cell therapy is expected to increase substantially. This innovative therapy's effectiveness can be enhanced through personalized approaches, which align treatment more closely with individual patient profiles. Such customization not only improves patient outcomes but also drives interest among healthcare professionals and organizations. As personalized medicine continues to take center stage in therapeutic developments, the CAR T-cell therapy market is likely to benefit immensely from this shift in focus towards individualized treatment strategies.

Restraints in the Global CAR T-Cell Therapy Market

The global CAR T-cell therapy market faces significant challenges related to the innovative nature of this treatment approach. Despite extensive testing, concerns about potential side effects and long-term safety remain prominent. These uncertainties are likely to limit the widespread acceptance and utilization of CAR T-cell therapy among healthcare providers and patients. As stakeholders in the market weigh the benefits against these risks, the hesitation to fully embrace this groundbreaking therapy could hinder its growth and integration into standard treatment protocols, impacting overall market development in the foreseeable future.

Market Trends of the Global CAR T-Cell Therapy Market

The Global CAR T-Cell Therapy market is witnessing a significant trend towards the development of allogeneic CAR T-cell therapies, which promise to streamline the manufacturing process by eliminating the need for patient-specific customization. This innovation is expected to enhance the accessibility and affordability of CAR T-cell treatments, broadening their market appeal. As companies focus on developing these therapies, they aim to not only improve patient outcomes but also position themselves favorably in emerging markets. This strategic shift will likely bolster growth opportunities within the sector, allowing providers to expand their business scope while catering to a diverse patient population.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global CAR T-Cell Therapy Market Size by Product & CAGR (2026-2033)

• Market Overview
• Yescarta
• Kymriah
• Carvykti
• Abecma
• Tecartus
• Breyanzi
• Other Products

Global CAR T-Cell Therapy Market Size by Target & CAGR (2026-2033)

• Market Overview
• CD19
• BCMA
• HER2
• Other Targets

Global CAR T-Cell Therapy Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Multiple Myeloma
• B-Cell Lymphoma
• Acute Lymphoblastic Leukemia
• Other Indications

Global CAR T-Cell Therapy Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Monotherapy
• Combination therapy

Global CAR T-Cell Therapy Market Size by Demographic & CAGR (2026-2033)

• Market Overview
• Adults
• Pediatrics

Global CAR T-Cell Therapy Market Size by Administration Type & CAGR (2026-2033)

• Market Overview
• Inpatient
• Outpatient

Global CAR T-Cell Therapy Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Centers
• Academic & Research Institutes

Global CAR T-Cell Therapy Market Size & CAGR (2026-2033)

• North America (Product, Target, Indication, Therapy Type, Demographic, Administration Type, End User)
  • US
  • Canada
• Europe (Product, Target, Indication, Therapy Type, Demographic, Administration Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Target, Indication, Therapy Type, Demographic, Administration Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Target, Indication, Therapy Type, Demographic, Administration Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Target, Indication, Therapy Type, Demographic, Administration Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Legend Biotech (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allogene Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellectis (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Precision BioSciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arcellx (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Autolus Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immatics N.V. (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caribou Biosciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tessa Therapeutics (Singapore)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorrento Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Precigen, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SinoCellTech (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celyad Oncology (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Instil Bio (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Poseida Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nkarta, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tmunity Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Innovative Cellular Therapeutics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Miltenyi Biotec (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prescient Therapeutics (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations